semaj83/ctmatch_classification huggingface dataset:
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Esophageal Cancer Endoscopically and histologically confirmed cancer of esophagus Progressive dysphagia caused by esophageal cancer, and the dysphagia grade of level Ⅲ or level Ⅳ[STOOLER stand] In barium meal of esophagus, severe stricture of the cancer make the barium difficult to pass through and the superior normal esophagus broaden The bulk and shape of the oesophageal cancer displayed by CT three-dimensional reconstruction Patients with clear consciousness，Cooperation，ECOG performance status of 0,1 and 3 Informed consent: authorization and signature  Poor general status,ECOG performance status of 4 Dysphagia not caused by esophageal cancer Noncooperation or no authorization and signature The superior border of cancer higher than the seventh cervical vertebrae Ulcerative esophageal carcinoma Esophageal fistulas WBC less than 3000/mm3 Severe hepatic inadequacy or renal inadequacy
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 3.0-45.0,  Pharyngitis patients with sore throat, classified 2-3 according to Cantor`s  patients on antibiotic treatment suspected carriers of streptococcus
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms, Lung Carcinoma, Non-Small Cell Lung Drug Therapy Genes, EGFR Male and female patients aged over 18 years Histologically proven lung adenocarcinoma clinical stage IIIB/IV ECOG performance status 0-2 Had no prior anticancer agent, radiation or surgical therapy for lung adenocarcinoma At least one measurable lesion (according to Provision of written informed consent Life expectancy of at least 12 weeks  History of malignant disease Evidence of clinically active interstitial lung diseases (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded) Expected life expectancy less than 2 months As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥ 2.5 x ULN if no demonstrable liver metastases (or >5 x in presence of liver metastases) Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study Pregnancy or breast-feeding women (women of child¬bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 0.0-70.0,  Thoracic Esophageal Squamous Cell Carcinoma Age≤70 years old Karnofsky Performance Status（KPS）≥80 Pathological diagnosis is squamous cell carcinoma of thoracic esophageal which is treated initially Clinical stage is c T 1 ~ 3 N 0 ~ 1 according to the results of endoscopic ultrasonography，chest and abdomen CT and neck ultrasonic The preoperative evaluation of organ function is tolerant of surgery and chemotherapy The subject can understand and sign the informed consent form (ICF) The following laboratory tests, made in 4 weeks before first medication, confirmed that bone marrow, liver and kidney function in line with the requirements to participate in research; Hemoglobin（HGB）≥9.0g/L; absolute neutrophils count（ANC）≥1.5×109/L; platelet count（PLT）≥100×109/L; total bilirubin（TBIL）≤1.5N;aspartate aminotransferase (AST)≤2.5N;alanine aminotransferase(ALT)≤2.5N;prothrombin time(PT)≤1.5N, and activated partial thromboplastin time(APTT) is in normal range;endogenous creatinine clearance rate(CRE)≤1.5N  Cervical esophageal cancer and Non-squamous cell carcinoma of thoracic esophageal cancer Advanced Esophageal Cancer Prior malignancy in 5 years recently History of previous chest radiotherapy History of cardio-cerebral vascular accident in 6 months lately The subject can not understand and sign the informed consent form(ICF)
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Smoking Body Weight The selection for the clinical trial are designed to a wide range of participants such that the study sample will be representative of the broader U.S. population of the Memphis metropolitan area. Those who might be at risk of adverse outcomes from the study interventions will be excluded (see  ). All participants will give voluntary consent at the screening visit by signing an informed consent statement which has been approved by the Institutional Review Board (IRB). We will encourage the participation of women and minorities. The study will be open to all persons of any race or gender who are *18 to 35 years old BMI > 22 kg / m2 Self report smoking > 10 cigarettes each day Have access to a telephone and the internet Demonstrate ability to access a specific web site Demonstrate ability to receive and respond to email Willing to accept random assignment *Intending to be available for a 24 month intervention *At risk for weight gain (e.g. plan to quit smoking)
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Adenocarcinoma of the Gastroesophageal Junction Esophageal Cancer Histologically confirmed esophageal cancer or gastroesophageal junction tumor including the following subtypes Adenocarcinoma Squamous cell cancer Poorly differentiated epithelial malignancy Gastroesophageal junction with Siewert type I or II tumors Failure after no more than 2 prior chemotherapy regimens and 1 chemoradiation course Measurable or evaluable disease by CT scan Patients with brain metastases must be stable and have received cranial irradiation prior to entry WHO performance status 0-2 Serum bilirubin ≤ 3 times the upper limit of normal (ULN)
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Cough Male and female subjects, age 18 years and over History of cough for more than 8 weeks Normal chest x ray Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers  Smoking status Current smokers Ex smokers with history of smoking > 20 pack years or those who have given up < 6 months ago Prohibited medications Use of medications likely to suppress / affect cough including codeine, morphine, pregabalin, gabapentin, amitriptylline, angiotensin converting enzyme inhibitors (type 1) and baclofen Use of any anti-arrhythmic medication Use of cimetidine, beta blockers, or diuretics Cardiovascular conditions Sinoatrial disease, bradycardia or all types of heart blocks History of ischaemic heart disease or heart failure
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 21.0-90.0,  Dysphagia Stroke identified by neurological and radiological examination Oropharyngeal dysphagia as confirmed by clinical and radiological examination No prior history of oropharyngeal dysphagia by patient and/or caregiver report No previous head/neck surgery or trauma that may impact swallowing ability No other/concomitant neurological disorders (e.g. Parkinson's disease) that would impact oropharyngeal swallowing ability. This does not post-stroke deficits Physician and patient/family agreement to participate  Exposed to previous behavioral or NMES swallowing therapy within 6 months of admission Presence of progressive neurological disorder, such as ALS; Parkinson's or other neurologic disorders within the last 6 months History of neurosurgery (either ablative or stimulatory), encephalitis or significant head trauma History of a significant medical condition such as heart, liver, or renal disease; history or evidence of malignancy within the past 5 years other than excised basal cell carcinoma Because of FDA Warnings, patients with cardiac demand pace makers will be excluded Patients with evidence of significant cognitive impairment or dementia as reflected in a Mini-Mental test less than 23 and/or a score of 50% or less on the comprehension quotient on the Western Aphasia Battery
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 70.0-85.0,  Esophageal Cancer Histologically documented diagnosis of esophageal Cancer Disease must be encompassed in a radiotherapy field.Patients with celiac, perigastric, mediastinal or supraclavicular adenopathy are eligible age:70-85 years Written informed consent Performance status of 0 to 2 Neutrophil count >1.5 x 10 to the 9th power/L and platelets > 100 x 10 to the 9th power/L Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN) Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN (or less than or equal to 5 times ULN in case of known liver involvement Renal: Serum Creatinine less than or equal to 1.5 times upper limit of normal (ULN)  Evidence of tracheoesophageal fistula, or invasion into the trachea or major bronchi Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) Prior systemic chemotherapy or radiation therapy for esophageal cancer
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms Patients with a confirmed diagnosis of advanced, measurable or evaluable, nonresectable and/or metastatic non-hematologic malignancy, which has shown to be progressive in the last 6 months as demonstrated by serial imaging Patients who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not amenable to established treatment options Tumour tissue must be available for the determination of E-cadherin expression (archived tissue or fresh biopsy) Recovery from reversible toxicities (alopecia excluded) of prior anti-cancer therapies (CTCAE grade < 2) Age = 18 years Life expectancy = 3 months Written informed consent in accordance with International Conference on Harmonisation/Good Clinical Practice (ICH/GCP) and local legislation, including consent for PK samples, for using an archived tumour sample for determination of Ecadherin status, for reviewing previous tumour scans (and for providing skin biopsies, in patients in dose finding phase enrolled before protocol amendment 03) Eastern Cooperative Oncology Group (ECOG), R01-0787) performance score 0-1 Additional in the expansion phase Patients must have measurable progressive disease within the last 6 months, according to Response Evaluation in Solid Tumours (RECIST) (version 1.1, R09-0262)  Serious concomitant non-oncological disease/illness Active/symptomatic brain metastases Second malignancy Pregnancy or breastfeeding Women or men who are sexually active and unwilling to use a medically acceptable method of contraception Treatment with cytotoxic anti-cancer-therapies or investigational drugs within four weeks of the first treatment with the study medication
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Gastric Cancer Adenocarcinoma of the Gastro-oesophageal Junction Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease not amenable to curative therapy Measurable disease, according to the Response Evaluation in Solid Tumours (RECIST), assessed using imaging techniques (CT or MRI) ECOG Performance status 0, 1 or 2 (see Appendix 2) Life expectancy of at least 3 months Male or female age ≥ 18 years Signed informed consent Assessment of HER2 status (primary tumour or metastasis) by the central laboratory prior to initiation of study treatment (see section 9.1) Able to swallow and retain oral medication LVEF ≥ 50% assessed by multigated radionucleotide angiography (MUGA) or cardiac ultrasound  Any of the following will the patient from the study Previous chemotherapy for advanced/metastatic disease (prior peri-operative chemotherapy is allowed if at least 6 months has elapsed between completion of this therapy and enrolment into the study) Previous radiotherapy on the abdomen Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma Patients with active (significant or uncontrolled) gastrointestinal bleeding Residual relevant toxicity resulting from previous therapy (with the exception of alopecia), e.g. neurological toxicity ≥ grade 2 NCI-CTCAE Creatinin clearance <50 mL/min Neutrophil count <1.5 × 109/L, or platelet count <100 × 109/L Serum bilirubin >1.5 × upper limit of normal (ULN); or, AST or ALT >2.5 × ULN (or >5 × ULN in patients with liver metastases); or, alkaline phosphatase >2.5 × ULN (or >5 × ULN in patients with liver metastases, or >10 × ULN in patients with bone but no liver metastases); or, albumin <25 g/L Known dihydropyrimidine dehydrogenase (DPD) deficiency
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Dysphagia Esophageal Cancer Age ≥18 years Confirmed esophageal/gastroesophageal (GEJ) cancer (Siewert Type I and Type II only) of any histology on biopsy Dysphagia score ≥2 Stage IV cancer/Metastatic disease  Expected life expectancy < 3 months Inability to undergo stent insertion Siewert Type III gastroesophageal cancer Esophageal-Airway fistula
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Metastatic or Recurrent Gastric Adenocarcinoma Her-2 Positive Gastric Cancer Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy Measurable disease, according to the Response Evaluation in Solid Tumors (RECIST), assessed using imaging techniques (CT or MRI) HER2 positive tumour (primary tumour or metastasis) defined as either IHC2+ and FISH+ or IHC3+ according to the gastric cancer scoring system for HER2 ECOG Performance status 0, 1 or 2 Life expectancy of at least 3 months Male or female. Age over 20 year Signed informed consent  Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study; adjuvant/neoadjuvant therapy with platinum is not allowed) Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not those with a jejunostomy tube) Patients with active (significant or uncontrolled) gastrointestinal bleeding Residual relevant toxicity resulting from previous therapy (with the exception of alopecia), e.g. neurological toxicity over grade 2 NCI-CTCAE Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma Neutrophil count < 1.5 × 109/L, or platelet count < 100 × 109/L Serum bilirubin > 1.5 × upper limit of normal (ULN); or, AST or ALT > 2.5 × ULN (or > 5 × ULN in patients with liver metastases); or, alkaline phosphatase > 2.5 × ULN (or > 5 × ULN in patients with liver metastases, or > 10 × ULN in patients with bone but no liver metastases); or, albumin < 25 g/L Creatinine clearance < 60 mL/min. Other Study Drug-Related History of documented congestive heart failure; angina pectoris requiring medication; evidence of transmural myocardial infarction on ECG; poorly controlled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg); clinically significant valvular heart disease; or high risk uncontrollable arrhythmias Baseline LVEF < 50% (measured by echocardiography or MUGA)
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 12.0-75.0,  Laryngopharyngeal Reflux Patients with age of 12-75 years old (inclusive) Patients with at least one symptom consistent with LPR, including hoarseness, throat clearing, throat pain, globus sensation in the throat, or chronic cough ≧ 4 weeks before entering study Patients with a total reflux symptom index (RSI) >10 (based on a self-administered 9-item questionnaire of voice/throat complaints) Patients with a total reflux finding score (RFS) >5 (based on a laryngoscopic examination by investigators) Patients or their legal representatives have signed the informed consent form  Patients with viral or bacterial laryngitis, or occupational exposures causing laryngitis Patients with erosive GERD as evidenced by upper GI endoscopy Patients with laryngeal or hypopharyngeal cancer, esophageal or gastric cancer, , or with history of neck radiation therapy Patients with history of uncontrolled hypertension or moderate to severe renal impairment Patients with history of esophageal or gastric surgery Patients with active pulmonary infection (pneumonia, tuberculosis) as evidenced by chest X-ray Patients with endotracheal tube intubation within 2 months before entering study Patients had taken any alginate preparations within 2 days; H2-blocker, prokinetic agent or antacid within 7 days; or proton pump inhibitors (PPIs) within 14 days before screening Patients with a history of allergy to the study drugs or their related compounds Patients with a history of alcohol or drug abuse, or with any psychiatric disease